The Clinical Significance of Aspirin Resistance in Patients With Chest Pain

Aydınalp, Alp; Atar, İlyas; Gülmez, Öykü; Atar, Asli; Açıkel, Sadık; Bozbaş, Hüseyin; Ozgül, Aliseydi; Ertan, Cagatay; Özin, Bülent; Müderrisoğlu, Haldun

doi:10.1002/clc.20539

Cited by 5 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among patients admitted to the emergency room with chest pain, Aydinalp et al 55 showed nearly a 2-fold increase in the prevalence of aspirin resistance, using the PFA-100 assay, in those patients with a confirmed diagnosis of ACS compared to those who had been ruled out for ACS (40.7% vs 17.2%). Similarly, patients with acute MI (NSTEMI or STEMI) are more likely to be aspirin resistant than in those without acute infarction.…”

Section: Post-acsmentioning

confidence: 99%

Aspirin Resistance: Current Status and Role of Tailored Therapy

Grinstein

Cannon

2012

Clinical Cardiology

View full text Add to dashboard Cite

Aspirin is integral in the primary and secondary prevention of coronary artery disease and acute coronary syndrome. Given the high clinical importance of aspirin in the management of coronary artery disease, much attention has been directed towards the concept of “aspirin resistance.” Unfortunately, the term aspirin resistance is ill‐defined in the literature, leading to a large variance in the reported prevalence of this phenomenon. In this review, the current understanding of aspirin resistance is discussed. Commonly used functional and diagnostic tests of platelet function, including their strengths and weakness, are reviewed. We next discuss several proposed mechanisms of aspirin resistance and special high‐risk groups at risk for aspirin treatment failure. We then discuss optimal dosing and diagnostic strategies for those populations at risk for aspirin resistance with a focus on tailored aspirin therapy for high‐risk groups. Finally, future topics of interest in the field of aspirin resistance are considered. Clin. Cardiol. 2012 doi: 10.1002/clc.22031Jonathan Grinstein has no funding, financial relationships, or conflicts of interest to disclose. Christopher P. Cannon receives research grants/support from the following companies: Accumetrics, AstraZeneca, Essentialis, GlaxoSmithKline, Merck, Regeneron, Sanofi, and Takeda. He is also on the advisory board (but funds donated to charity) for Alnylam, Bristol‐Myers Squibb, and Pfizer. He is a Clinical Advisor, equity in Automedics Medical Systems.

show abstract

Section: Post-acsmentioning

confidence: 99%

Aspirin Resistance: Current Status and Role of Tailored Therapy

Grinstein

Cannon

2012

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…High on-treatment platelet reactivity is linked to worse outcomes for both STEMI and NSTEMI patients undergoing procedures [17]. Platelet reactivity and anti-platelet resistance is suggested to be higher in STEMI patients than NSTEMI patients [18-20]. These differences in platelet reactivity and disease progression may result from gene expression differences between STEMI and NSTEMI cases.…”

Section: Introductionmentioning

confidence: 99%

Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction

et al. 2015

View full text Add to dashboard Cite

Transcripts in platelets are largely produced in precursor megakaryocytes but remain physiologically-active as platelets translate RNAs and regulate protein/RNA levels. Recent studies using transcriptome sequencing (RNA-seq) characterized the platelet transcriptome in limited numbers of non-diseased individuals. Here, we expand upon these RNA-seq studies by completing RNA-seq in platelets from 32 patients with acute myocardial infarction (MI). Our goals were to characterize the platelet transcriptome using a population of patients with acute MI and relate gene expression to platelet aggregation measures and ST-segment elevation MI (STEMI) (n=16) versus non-STEMI (NSTEMI) (n=16) subtypes. Similar to other studies, we detected 9,565 expressed transcripts, including several known platelet-enriched markers (e.g., PPBP, OST4). Our RNA-seq data strongly correlated with independently ascertained platelet expression data and showed enrichment for platelet-related pathways (e.g., wound response, hemostasis, and platelet activation), as well as actin-related and post-transcriptional processes. Several transcripts displayed suggestively higher (FBXL4, ECHDC3, KCNE1, TAOK2, AURKB, ERG, and FKBP5) and lower (MIAT, PVRL3and PZP) expression in STEMI platelets compared to NSTEMI. We also identified transcripts correlated with platelet aggregation to TRAP (ATP6V1G2, SLC2A3), collagen (CEACAM1, ITGA2), and ADP (PDGFB, PDGFC, ST3GAL6). Our study adds to current platelet gene expression resources by providing transcriptome-wide analyses in platelets isolated from patients with acute MI. In concert with prior studies, we identify various genes for further study in regards to platelet function and acute MI. Future platelet RNA-seq studies examining more diverse sets of healthy and diseased samples will add to our understanding of platelet thrombotic and non-thrombotic functions.

show abstract

“…What is inspiring is that the contribution of countries such as Turkey played a bigger role in producing articles related to aspirin resistance. Several studies conducted in Turkey reported a high frequency of aspirin resistance in patients with kidney failure [72,73], acute coronary syndrome [74][75][76], hypertension [77], chest pain [78], metabolic syndrome [79,80], diabetes mellitus [81], stroke [76], systemic lupus erythematosus [82] and cigarette smoking [83]. These results might open the door for new ideas and questions for research related to aspirin resistance.…”

Section: Discussionmentioning

confidence: 99%

Global Trends in Aspirin Resistance‐Related Research from 1990 to 2015: A Bibliometric Analysis

Al-Jabi

2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Aspirin resistance can be defined as the inability of the usual dose of aspirin medication to produce its antithrombotic effect. Patients with diabetes or cardiovascular disease are at higher risk of stroke, myocardial infarction or cardiovascular death due to aspirin resistance. The aim of this bibliometric study was to identify and analyse the status and trends of aspirin resistance research production at global level through publications indexed in the Scopus database; this will shed new light on future research trends and help researchers predict dynamic direction of research. Literature search using the Scopus database was conducted to assess publications related to aspirin resistance. The selected publications included the terms related to aspirin resistance in the title, abstract or keywords. The searching was accomplished on 20 March 2016 and can be considered to include all publications up to 31 December 2015. Global cumulative publication output on aspirin resistance consists of 986 papers during 1990-2015. Among the 986 documents, 19 (1.9%) were published before 2000, 567 (57.5%) were published from 2000 to 2009 and 400 (40.6%) were published from 2010 to 2015, with peak of publications on this topic in 2008. The leading country in the field of aspirin resistance was the United States, which had the greatest counts of independent articles (165) and international collaboration articles (44). Turkey was in the second rank with 78 articles, followed by Italy (68), the UK (62) and Poland (60). The total number of citations for all documents was 26,342, and the average citations per document were 26.7. The h-index for all aspirin resistance publications was 82. This study presents the results of the first bibliometric study (including quantitative and qualitative analysis) of scientific publications in the field of aspirin renitence at global level. Aspirin resistance-related researches have notably increased in the last years, especially from 2000 to 2015. The United States is the most prolific country, not only in research quantity but also in quality. Furthermore, Turkey and European countries provided more research related to aspirin resistance than other regions such as the developing countries.

show abstract

The Clinical Significance of Aspirin Resistance in Patients With Chest Pain

Cited by 5 publications

References 13 publications

Aspirin Resistance: Current Status and Role of Tailored Therapy

Aspirin Resistance: Current Status and Role of Tailored Therapy

Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction

Global Trends in Aspirin Resistance‐Related Research from 1990 to 2015: A Bibliometric Analysis

Contact Info

Product

Resources

About